Heart Transplantation

4
Pipeline Programs
7
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
1
Cyclosporine discontinuationPhase 41 trial
Building Research Initiative Group: Chronic Illness Management and Adherence in TransplantationN/A1 trial
Active Trials
NCT01608477Unknown1,365Est. Dec 2020
NCT00123331Completed40Est. Apr 2005
Astellas
AstellasChina - Shenyang
2 programs
1
FK506EPhase 31 trial
Building Research Initiative Group: Chronic Illness Management and Adherence in TransplantationN/A
Active Trials
NCT02118896Completed850Est. Oct 2009
Providence Therapeutics
1 program
1
Bortezomib, Thymoglobulin, Rituximab, Gamimune N,Phase 21 trial
Active Trials
NCT01556347TerminatedEst. May 2016
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
enriched hematopoetic stem cell infusionPhase 1/21 trial
Active Trials
NCT00497757CompletedEst. Dec 2016
XVIVO
XVIVOSweden - Mölndal
1 program
XVIVO heart preservation devicesN/A1 trial
Active Trials
NCT03991923Active Not RecruitingEst. Dec 2028
Roche
RocheSTAVANGER NORWAY, Norway
1 program
prednisolonN/A2 trials
Active Trials
NCT01948401Completed54Est. Apr 2014
NCT00359658Completed40Est. Jun 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Heidelberg PharmaCyclosporine discontinuation
AstellasFK506E
Rocheprednisolon
Providence TherapeuticsBortezomib, Thymoglobulin, Rituximab, Gamimune N,
T-Therapeuticsenriched hematopoetic stem cell infusion
XVIVOXVIVO heart preservation devices
Heidelberg PharmaBuilding Research Initiative Group: Chronic Illness Management and Adherence in Transplantation
Rocheprednisolon

Clinical Trials (8)

Total enrollment: 2,349 patients across 8 trials

NCT00123331Heidelberg PharmaCyclosporine discontinuation

Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation

Start: Oct 2003Est. completion: Apr 200540 patients
Phase 4Completed
NCT02118896AstellasFK506E

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Start: Feb 2003Est. completion: Oct 2009850 patients
Phase 3Completed
NCT01948401Rocheprednisolon

A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma

Start: Jul 2013Est. completion: Apr 201454 patients
Phase 2Completed
NCT01556347Providence TherapeuticsBortezomib, Thymoglobulin, Rituximab, Gamimune N,

Multi-Drug Desensitization Protocol for Heart Transplant Candidates

Start: Jul 2012Est. completion: May 2016
Phase 2Terminated
NCT00497757T-Therapeuticsenriched hematopoetic stem cell infusion

Induction of Donor Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion

Start: Jul 2003Est. completion: Dec 2016
Phase 1/2Completed
NCT03991923XVIVOXVIVO heart preservation devices

Non-ischemic Preservation of the Donor Heart in Heart Transplantation

Start: Nov 2020Est. completion: Dec 2028
N/AActive Not Recruiting
NCT01608477Heidelberg PharmaBuilding Research Initiative Group: Chronic Illness Management and Adherence in Transplantation

Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation

Start: Mar 2012Est. completion: Dec 20201,365 patients
N/AUnknown
NCT00359658Rocheprednisolon

Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation

Start: Nov 2004Est. completion: Jun 200840 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space